INTRODUCTION
S. aureus is an important human pathogen that causes a wide-range of infections and is the most common bacterium associated with septic arthritis. The disease often results in severe and persistent joint damage, and mortality rates from this type of infection are high (1, 2) .
Furthermore, S. aureus remains one of the most common causes of infections in the industrialized world and since the 1980s, S. aureus has become the most common nosocomial pathogen due, in part, to an increasing resistance to multiple antibiotics and to the recent worldwide emergence of highly virulent strains (1, (3) (4) (5) (6) (7) (8) (9) (10) (11) . In addition, S. aureus infections can result in a variety of diseases, including skin infections, endocarditis, arthritis, osteomyelitis, or sepsis and is a reflection of this organism's capacity to colonize a variety of different tissues and of their ability to circumvent a variety of immune surveillance systems resulting in the persistence of S. aureus in different environments within the host organism (1, (12) (13) (14) .
The ability of S. aureus to affect such diverse tissues and cause persistent infections is in part related to their ability to manipulate or evade multiple defense mechanisms (1, (12) (13) (14) (15) (16) (17) .
Pathogens associated with persistent infections often produce multiple MIMs (Microbial Immunomodulatory Molecules) (12, 17) to counter the host's immune systems (i.e. adaptive and innate immunity, respectively) (12, 17) and this strategy results in the effective avoidance or delay of the pathogen's clearance while concomitantly affecting the development of a protective memory response. Well-characterized members of the S. aureus MIM family of proteins are the Super Antigens and Protein A, which can affect T cell and antibody responses, respectively (1).
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function and neutrophil migration (12, 24) , and the Chemotaxis Inhibitory Protein from S. aureus (CHIPS) (13, 25) that interferes with the inflammatory response early in the infection process by binding to the C5a-and formylated peptide-receptors.
One of the central components of innate immunity is the complement system. Activation of the complement pathways (i.e. classical, mannose-binding lectin or alternative pathways) can lead to opsonization and phagocytosis of invading pathogens and, in a majority of cases, complement mediates lysis and cell death (26) . Furthermore, complement component byproducts (e.g. C3a and C5a) can serve as potent chemoattractants for numerous inflammatory cells (27) . A central component to all three pathways is the complement protein C3 (26, 28) . C3
is not only critical for complement pathway activation, but it also plays a pivotal role in the interface between innate and acquired immune responses (28). Patients with a C3 deficiency have a significantly impaired complement system and have an increased susceptibility to infections from a variety of organisms (29) (30) (31) . Many successful human pathogens have evolved either direct C3-inactivation strategies by producing C3-binding proteins (e.g. S. aureus, Trypanosoma cruzi and Pseudomonas aeruginosa) (17, (32) (33) (34) To date most work describing the interactions between S. aureus and complement components has primarily focused on the role of the capsule as a means of preventing C3 deposition and C3-mediated opsonization of S. aureus (50) (51) (52) . However, many virulent S. aureus strains do not form a capsule (53, 54) , suggesting that other complement-inhibitory strategies are likely. A recent report from our laboratory demonstrated that the S. aureus protein Efb binds to C3b and inhibits both complement-mediated lysis and opsonophagocytosis via a mechanism that inhibit C3b deposition onto activator surfaces (17) .
Efb is a secreted, constitutively expressed protein that also binds fibrinogen. In addition, the efb gene was present in all S. aureus isolates examined but not identified in any other staphylococcal species (21) .
Investigations into the roles of Efb in vivo have resulted in various hypotheses describing functions for Efb and include roles for Efb in potentiating S. aureus survival by delaying wound healing and by inhibiting platelet aggregation via its interactions with fibrinogen and the platelet receptor GPIIb/IIIa (23, 55) . Furthermore, these studies suggested that the fibrinogen-binding domains were located at the N-terminus of Efb and consisted of two 22-amino acid repeats with homology to the fibrinogen-binding domains of coagulase from S. aureus (56) . A third fibrinogen-binding domain was also reported to reside in the C-terminal end of the protein, however, the fibrinogen-binding activity of this site was less-well defined since binding was dependant on whether fibrinogen was soluble or plate-bound (22, 57, 58) . reverse primer for efb, efb104, efb120 and efb165, respectively (IDT Inc., Coralville, IA, USA).
The resulting PCR products were subsequently cloned using the TA Expression Kit into the pCRT7/NT-TOPO expression vector (Invitrogen, Carlsbad, CA, USA) and designated pCRT7/NT-rEfb, pCRT7/NT-rEfb104, pCRT7/NT-rEfb120, and pCRT7/NT-rEfb165.
Nucleotide sequencing of efb, efb104, efb120, and efb165 was performed by automated sequencing (Molecular Genetics Core Facility, University of Texas-Houston Medical School).
The recombinant proteins rEfb (17), rEfb104, rEfb120, and rEfb165 were expressed as recombinant N-terminal His-tagged proteins that allowed for purification using metal ionchelating chromatography as described previously (12, 59) . Proteins were expressed and purified as previously described (59, 60) . Protein concentrations were determined by UV spectroscopy and proteins were stored at -20°C until use. Circular Dichroism (CD)-rEfb, rEfb104, rEfb120, and rEfb165 were dialyzed twice in 2L
10 mM potassium phosphate buffer ph 7.4 and their respective concentrations determined using UV spectroscopy. CD spectra were obtained using a Jasco J-720 spectropolarimeter (Jasco Inc., 
RESULTS

rEfb Binds to the C3d Fragment of C3-Identifying the binding site(s) in C3b for rEfb was
performed by testing the binding of rEfb to various C3b a-chain fragments generated during the process of complement activation. During this process, C3 undergoes multiple cleavage events which generate various fragments which include C3a, C3b, iC3b, C3c, C3d, C3dg, and C3g (64).
To determine which C3 fragment bound to rEfb, the C3 protein fragments C3b, iC3b, C3c, and
C3d were subjected to SDS-PAGE and Coomassie-stained (Fig. 1A) or transferred onto a PVDF membrane and probed with rEfb (Fig. 1B) . Western-ligand blot analysis demonstrated that rEfb bound to C3d and all C3d-containing fragments. C3c, which does not contain the C3d region, did not bind rEfb (Fig. 1B) . The additional a-chain fragment of approximately 58 kDa ( Secondary Structural Analysis of rEfb-The C3d region contains binding sites for two complement-regulatory proteins of the Factor H family, CR2 and Factor H. Factor H is a soluble C3b; SCR6-10 which binds to C3c; and SCR16-20 which binds to C3d), and each domain has been defined as a six-stranded anti-parallel b-sheet structure (65,68), we examined, using circular dichroism (CD) spectroscopy, if rEfb shared any structural similarity to Factor H .
The secondary structure of rEfb was analyzed using CD spectroscopy and the PHD (Profile network prediction Heidelberg) program (69, 70) . Both analyses revealed that rEfb was largely a helical ( Fig. 2 and Table Ia ) and composed of 2 domains, neither of which had any structural similarity to the SCR motif. To identify the region(s) of rEfb containing the a-helices, 2 constructs (rEfb104 and rEfb120) spanning the N-terminal half of rEfb and one C-terminal construct (rEfb165) (Fig. 3) , were generated and examined in a similar manner ( Fig. 2 and Table   Ia ). There is a 25 amino acid overlap between the C-terminus of rEfb120 and the N-terminus of rEfb165 ( Figure 3) . The results of the CD analyses and the secondary structure predictions for rEfb and the rEfb constructs is shown in Table Ia . The CD analysis data suggested that rEfb contains an a-helical C-terminal region and an unordered N-terminal domain (which contains the two fibrinogen-binding repeats) (19) since rEfb165 contains almost the same percent of a-helix as rEfb. Conversely, rEfb104 is highly unordered with some b-sheet (Table Ia) . The CD data collected for rEfb120 suggested that the 25 amino acids at its C-terminus (shared with rEfb165)
are responsible for some of the a-helix observed in this construct. The predicted secondary structure predictions mirror the CD in that this analysis also indicated that the a-helices were located at the C-terminus (rEfb165) with little or no structure at the N-terminus (rEfb104) ( Table   Ia ). The differences in the nature of the predicted structure and the structural data collected by CD spectroscopy for some of the rEfb constructs suggests that secondary structure prediction programs should be used cautiously since some disparity exists between the structural data collected by CD and the predicted structures for some of the rEfb constructs.
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The C-terminus of rEfb Binds to C3b but not Fibrinogen-Determining the location of the C3b-binding region in rEfb was initially examined by Western-ligand blot analysis. rEfb, rEfb120, and rEfb165 were subjected to SDS-PAGE and Coomassie-stained (Fig. 4A ) or transferred onto a PVDF membrane and probed with either digoxigenin-labeled C3b (Fig. 4B ) or digoxigenin-labeled fibrinogen (Fig. 4C) . Western blots probed with C3b demonstrated that rEfb and rEfb165 bound C3b but that rEfb120 did not (Fig. 4B) . Conversely, Western blots probed with fibrinogen demonstrated binding to rEfb and rEfb120 but not to rEfb165 (Fig. 4C ). Blots probed with an AP-labeled secondary antibody alone revealed no color change following the addition of substrate (data not shown). rEfb104 bound to fibrinogen but did not bind C3b (data not shown). Similar results were obtained using ELISA-type binding assays. rEfb and rEfb165
bound to plate-bound C3b and rEfb, rEfb104 (data not show), and rEfb120 bound plate-bound fibrinogen in a dose-dependent and saturable manner (Fig. 5A-B ). rEfb120 and not rEfb104 was used in these experiments and in all subsequent studies.
The C-terminal Domain of rEfb Inhibits Complement Activation-We previously reported
that rEfb interfered with both classical and alternative pathways of complement activation (17) .
To determine if the rEfb165-C3b interaction could also affect complement activity, we examined the effect of rEfb165 in a functional assay measuring classical pathway activity. This assay utilizes RBC lyses as a read-out for complement activity. Data presented in Fig. 6 demonstrated that both full-length rEfb and rEfb165 inhibited complement-mediated RBC lysis to the same degree, in contrast, rEfb120 had no inhibitory activity. fibrinogen was immobilized on microtiter wells and probed first with either rEfb, rEfb120, or rEfb165 followed by a subsequent incubation with digoxigenin-labeled C3b (Fig. 7A) . These results demonstrated that rEfb but not rEfb120 or rEfb165 could bind to C3b and fibrinogen simultaneously (Fig. 7A) . As a control, anti-His antibodies were used to detect binding of the recombinant proteins to fibrinogen (Fig. 7B) . The anti-His antibodies recognized the fibrinogenbound rEfb and rEfb120, however, rEfb165 which does not bind fibrinogen, was not detected (Fig. 7B and Fig. 4C ). Molecules) (72), a family of adhesins which mediate adhesion to host ECM components (18) (19) (20) 24) ; emphasizing the importance of both parameters in establishing an infection. In the case of Efb, which inactivates complement-mediated lysis and phagocytosis (by binding to C3b) (17) and to delay clot formation and wound healing via a mechanism that involves fibrinogen binding (23, 73) , further illustrate the pleiotropic properties of many of these molecules.
Determination of the Kd-Intrinsic
In this study, we have identified the region of rEfb associated with C3b binding to be within the C-terminus, in contrast to the fibrinogen-binding domains that reside within the Nterminal half of the protein. Western-ligand blot and ELISA-type binding assays demonstrated that the C-terminal construct rEfb165 bound exclusively to C3b but not to fibrinogen;
conversely, the N-terminal constructs rEfb104 and rEfb120 bound exclusively to fibrinogen but not to C3b. This finding is somewhat contradictory to previous data that suggested that Efb contained a third fibrinogen-binding site in the C-terminus region. DNA sequence analysis of the cloned refb165 used in this study was consistent with sequence data identified in NCBI nucleotide database (Q08691) and did not contain any mismatches or mutations. One explanation for this difference in fibrinogen binding is that the previous studies examined synthetic Efb peptides for fibrinogen-binding in addition to using soluble fibrinogen as a probe in ELISA-type binding assays (22) . Earlier work from the same laboratory demonstrated that binding of rEfb to fibrinogen occurred only to solid-phase but not soluble fibrinogen (56) suggesting that the conformation of fibrinogen may be important for Efb binding, however, in our hands neither solid-or soluble-phase fibrinogen (data not shown) bound to rEfb165 in ELISA-type binding assays. is not known and will be the subject for future work. However, since rEfb can also inhibit classical pathway activation (17) (Table Ib) revealed that the majority of these proteins are surface-associated and from intracellular pathogens (exceptions being T. cruzi and P . aeruginosa) (32, 34, 77) (Table Ib) and all except P. aeruginosa (77) utilize these proteins primarily as a means of gaining entry into cells via CR1/2 (Table Ib) . In addition, these proteins range in size and their predicted secondary structures vary significantly. Even though proteins such as CbpA, MOMP, and LPG (Table Ib) have a similar predicted secondary structure to that of rEfb, the specific C3-binding sites in these proteins have not yet been defined and it would therefore be unwise to speculate as to the nature of the secondary structure(s) involved with C3-binding for these and the other C3-binding proteins listed in Table Ib . No amino acid sequence similarity between Efb and any of the proteins listed in Table Ib was Representative modified Stern-Volmer plot of the data acquired from the fluorescence quenching assay was used to determine the Kd value of 0.24 µM (C).
